Novo Nordisk in Talks for Controlling Stake of BIOCORP for Its Smart Injector Pen

Novo Nordisk and BIOCORP have entered into negotiations for Novo Nordisk to acquire a controlling stake in BIOCORP, a French company which has been developing a Bluetooth enabled smart add-on device for insulin pen injectors.

The companies have been collaborating since 2021 on the development and commercialization of the Mallya add-on device for the Novo Nordisk FlexTouch insulin pen, and are working on expanding “the development of versions of the Mallya device for other therapy areas,” the company said.

The companies say they expect the $165 million deal to close in the third quarter of this year.

Related Topics